1470 related articles for article (PubMed ID: 17472819)
1. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
3. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
Hanrahan JP; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Baumgartner RA
COPD; 2008 Feb; 5(1):25-34. PubMed ID: 18259972
[TBL] [Abstract][Full Text] [Related]
4. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
[TBL] [Abstract][Full Text] [Related]
6. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
8. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
10. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
12. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of arformoterol and formoterol in COPD.
Hanania NA; Donohue JF; Nelson H; Sciarappa K; Goodwin E; Baumgartner RA; Hanrahan JP
COPD; 2010 Feb; 7(1):17-31. PubMed ID: 20214460
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
15. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
16. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
17. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
[TBL] [Abstract][Full Text] [Related]
19. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]